202例肝功能异常患者病因分析

doi:10.3969/j.issn.1672-5069.2019.06.020

实用肝脏病杂志 ›› 2019, Vol. 22 ›› Issue (6): 856-859.doi: 10.3969/j.issn.1672-5069.2019.06.020

202例肝功能异常患者病因分析

丁利敏, 王飞, 朴莲淑, 张孟, 刘城, 李芊蔚, 徐德魁, 于庆功

116000 辽宁省大连市大连大学附属中山医院消化内科

收稿日期:2018-09-05 出版日期:2019-11-13 发布日期:2019-11-13
通讯作者: 于庆功,E-mail:yuqing-669@sohu.com
作者简介:丁利敏,女,28岁,硕士研究生。E-mail:814499524@QQ.com

Etiology of 202 patients with abnormal liver function tests

Ding Limin, Wang Fei, Piao Lianshu, et al.

Department of Gastroenterology,Zhongshan Hospital,Affiliated to Dalian University,Dalian 116000,Liaoning Province,China

Received:2018-09-05 Online:2019-11-13 Published:2019-11-13

摘要/Abstract

摘要： 目的探讨肝功能异常的常见病因。方法 2011年6月~2018年6月收治的202例肝功能异常患者,常规进行病因筛查。结果在202例住院的肝功能异常患者中,脂肪性肝病（NAFLD）62例（30.7%）、药物性肝损害（DILI）56例（27.7%）、自身免疫性肝病（AILD）18例（8.9%）、嗜肝病毒感染18例（8.9%）、肿瘤9例（4.5%）、肝硬化11例（5.5%）、胆道系统感染11例（5.5%）、非嗜肝病毒感染1例（0.5%）、中毒1例（0.5%）、营养不良2例（1.0%）和病因不明13例（6.4%）;青年组NAFLD、DILI和嗜肝病毒感染构成比分别为49.4%、16.9%和10.8%,中年组DILI、脂肪性肝病和AILD构成比分别为34.3%、25.4%和10.5%,老年组DILI、AILD和肿瘤构成比分别为36.5%、15.4%和13.5%;男性NAFLD、DILI和嗜肝病毒感染构成比分别为43.6%、20.0%和15.8%,女性DILI、脂肪性肝病和AILD构成比分别为35.6%、17.8%和14.9%。结论导致肝功能异常的病因较多,不同年龄和不同性别人群常见病因有所不同。

关键词: 肝功能异常, 病因, 分析

Abstract: Objective To investigate the etiology of 202 patients with abnormal liver function tests. Methods 202 patients with abnormal liver function tests were admitted to our Department of Gastroenterology,Zhongshan Hospital between June 2011 and June 2008. The etiologic examination was routinely conducted. Results Out of the 202 patients with abnormal liver function tests,fatty liver disease was found in 62 cases （30.7%）,drug-induced liver injuries （DILI） in 56 cases （27.7%）,autoimmune liver disease （AILD） in 18 cases （8.9%）,hepatotropic virus infection in 18 cases （8.9%）,tumor in 9 cases（4.5%）,liver cirrhosis in 11（5.5%）,bile duct infection in 11（5.5%）,non-hepatotropic virus infection in 1（0.5%）,toxic injuries in 1（0.5%）,malnutrition in 2（1.0%） and liver injury with unknown cause in 13（6.4%）;the percentages of NAFLD,DILI and hepatotropic virus infection in youth accounted for 49.4%,16.9% and 10.8%,the percentages of DILI,NAFLD and AILD in middle aged group accounted for 34.3%,25.4% and 10.5%,and the percentages of DILI,AILD and tumor in elderly group accounted for 36.5%,15.4% and 13.5%;the percentages of NAFLD,DILI and hepatotropic viral infection in men accounted for 43.6%,20.0% nd 15.8%,and those of DILI,NAFLD and AILD in women accounted for 35.6%,17.8% and 14.9%. Conclusion The causes of abnormal liver function tests are complex and diverse,and the common causes of it in different ages and different genders differ,which might help the clinicians to deal with them.

Key words: Liver injuries, Etiology, Analysis

丁利敏, 王飞, 朴莲淑, 张孟, 刘城, 李芊蔚, 徐德魁, 于庆功. 202例肝功能异常患者病因分析[J]. 实用肝脏病杂志, 2019, 22(6): 856-859.

Ding Limin, Wang Fei, Piao Lianshu, et al.. Etiology of 202 patients with abnormal liver function tests[J]. Journal of Practical Hepatology, 2019, 22(6): 856-859.

参考文献

[1] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南. 实用肝脏病杂志,2007,10(1):1-3.
[2] 中华医学会消化病学分会肝胆疾病协作组. 药物性肝损伤诊治建议(草案). 中华消化杂志,2007,27(11):765-767.
[3] 中华医学会风湿病学分会. 自身免疫性肝病诊断和治疗指南. 中华风湿病学杂志,2011,15(8):556-558.
[4] 病毒性肝炎防治方案. 中华传染病杂志,2001,15(1):55-61.
[5] Nigam SK. What do drug transporters really do Nat Rev Drug Discov,2015,14(1):29-44.
[6] Than NN,Newsome PN.A concise review of non-alcoholic fatty liver disease. Atherosclerosis,2015,239(1):192-202.
[7] Sanchez-Torrijos Y,Ampuero J,Romero-Gómez M.Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients:What we do,what we should do. World J Hepatol,2017,9(15):697-703.
[8] 管军,徐烨. 青少年非酒精性脂肪肝相关危险因素分析. 实用肝脏病杂志,2017,20(3):347-349.
[9] Issa D,Wattacheril J,Sanyal AJ.Treatment options for nonalcoholic steatohepatitis-a safety evaluation. Expert Opin Drug Saf,2017,16(8):903-913.
[10] Katarey D,Verma S.Drug-induced liver injury. Clin Med,2016,16(Suppl 6):s104.
[11] Fan JG,Farrell G C.Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol,2009,50(1):204-210.
[12] Wang F,Fan J,Zhang Z,et al.The global burden of liver disease:The major impact of China. Hepatology,2015,60(6):2099-2108.
[13] Byrne CD,Targher G.NAFLD:a multisystem disease. J Hepatol,2015,62(1):S47-S64.
[14] Abd ElKader SM,ElDen Ashmawy EM. Non-alcoholic fatty liver disease:The diagnosis and management. World J Hepatol,2015,7(6):846.
[15] Nascimbeni F,Pais R,Bellentani S,et al.From NAFLD in clinical practice to answers from guidelines. J Hepatol,2013,59(4):859-871.
[16] Kim J,Eisenberg D,Azagury D,et al.American Society for Metabolic and Bariatric Surgery position statement on long-term survival benefit after metabolic and bariatric surgery. Surg Obes Relat Dis,2016,12(3):453-459.
[17] Melissas J,Stavroulakis K,Tzikoulis V,et al.Sleeve gastrectomy vs Roux-en-Y gastric bypass. Data from IFSO-European Chapter Center of Excellence Program. Obes Surg,2016,27(4):1-9.
[18] Petriz BA,Castro AP,Almeida JA,et al.Exercise induction of gut microbiota modifications in obese,non-obese and hypertensive rats. BMC Genomics,2014,15:511.
[19] Clarke SF,Murphy EF,O'Sullivan O,et al. Exercise and associated dietary extremes impact on gut microbial diversity. Gut,2014,63(12):1913-1920.
[20] Bjornsson ES.Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis,2014,34(2):115-122.
[21] Conforti A,Leone R,Ghiotto E,et al.Spontaneous reporting of drug-related hepatic reactions from two Italian regions (lombardy and veneto). Dig Liver Dis,2000,32(8):716-723.
[22] de Boer YS,Kosinski AS,Urban TJ,et al. Features of autoimmune hepatitis in patients with drug-induced liver injury. Clin Gastroenterol Hepatol,2017,15(1):103.

202例肝功能异常患者病因分析

Etiology of 202 patients with abnormal liver function tests

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈帅, 杨长青. 门静脉血栓病因及危险因素研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 761-764.
[2]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[3]	张微, 史军梅, 王倩. 新生儿发生高胆红素血症危险因素分析[J]. 实用肝脏病杂志, 2019, 22(4): 534-536.
[4]	宋芳娇,朱冰,吕飒,田华,王海波,辛绍杰,游绍莉. 314例药物性肝衰竭患者临床特征分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 216-219.
[5]	王军艳, 陈建婷, 张婷, 范丽, 杜姗, 蒋承志, 牟花妮. 乙型肝炎肝硬化患者院内获得性感染相关危险因素分析^*[J]. 实用肝脏病杂志, 2019, 22(1): 101-104.
[6]	孙文静, 陈东风. UCAM和Maria诊断标准用于评估1352例中国人药物性肝损伤文献分析[J]. 实用肝脏病杂志, 2018, 21(6): 881-884.
[7]	崔瑞冰, 阎明. 腹水原因解析[J]. 实用肝脏病杂志, 2018, 21(5): 657-660.
[8]	李越, 丁惠国. 乳糜性腹水诊治现状^*[J]. 实用肝脏病杂志, 2018, 21(5): 665-668.
[9]	王庆治, 谢静. 2013~2015年乙型肝炎肝硬化患者住院费用调查分析[J]. 实用肝脏病杂志, 2018, 21(4): 597-600.
[10]	陈世耀, 黄晓铨, 曾晓清. 门脉高压症的检查选择与病因诊断*[J]. 实用肝脏病杂志, 2018, 21(3): 321-324.
[11]	章燕虹, 李游, 陈龙, 沈薇. 2890例住院的肝硬化患者病因和并发症分析*[J]. 实用肝脏病杂志, 2018, 21(3): 344-347.
[12]	陈小青, 王迎春. 肝内胆汁淤积性肝病的病因与治疗[J]. 实用肝脏病杂志, 2018, 21(2): 163-165.
[13]	张海月, 王鲁文, 刘菲菲, 龚作炯. 核苷（酸）类药物治疗HBeAg阳性CHB患者血清HBsAg水平变化Meta分析*[J]. 实用肝脏病杂志, 2018, 21(2): 191-195.
[14]	焦方舟, 张海月, 张文斌, 王鲁文, 龚作炯. 索非布韦联合α-干扰素治疗慢性丙型肝炎患者疗效比较的Meta分析[J]. 实用肝脏病杂志, 2018, 21(2): 220-224.
[15]	汪佩文, 董育玮, 李郑红, 姜海琼, 陆伦根. 94例不明原因肝功能异常患者临床与肝组织病理学分析*[J]. 实用肝脏病杂志, 2018, 21(2): 225-228.